MedTrace Logo

The Study Assessing the Safety and Efficacy of OK-101 Treatment in Subjects With Neuropathic Corneal Pain

NCT06637527 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2025-08-15

No results posted yet for this study

Summary

The primary objective of this study, in subjects with Neuropathic Corneal Pain, is to evaluate the efficacy and safety of OK-101 0.05% and 0.1% as compared to placebo instilled 4 times/day in subjects with neuropathic corneal pain, as assessed by visual analogue scale (VAS).

Conditions

  • Neuropathic Pain

Interventions

DRUG

OK-101 0.05%

0.05% Ophthalmic Solution

DRUG

OK-101 0.1%

0.1% Ophthalmic Solution

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Tufts Medical Center

    collaborator OTHER

  • Okyo Pharma Ltd

    lead INDUSTRY

Principal Investigators

  • Pedram Hamrah, MD · Tufts Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-15
Primary Completion
2025-04-30
Completion
2025-07-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06637527 on ClinicalTrials.gov